QIAGEN, Clovis Oncology Collaborate for Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
Companion diagnostic will run on QIAGEN’s efficient Rotor-Gene Q MDx platform.
Read MorePosted by Judy O'Rourke | Oct 21, 2013 | Cancer, Miscellaneous |
Companion diagnostic will run on QIAGEN’s efficient Rotor-Gene Q MDx platform.
Read MorePosted by Judy O'Rourke | Oct 17, 2013 | Cancer, Kidney Disease, Molecular Diagnostics, Research |
Examining 12 major types of cancer, scientists at Washington University School of Medicine in St Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body.
Read MorePosted by Judy O'Rourke | Oct 17, 2013 | Cancer, Miscellaneous, Research |
The effort will evaluate Trovagene’s proprietary, urine-based, cell-free DNA technology for the detection of certain EGFR mutations associated with lung cancer.
Read MorePosted by Judy O'Rourke | Oct 10, 2013 | Cancer |
The fruits of this collaboration will be a product and service that will facilitate production and use of standardized, encoded, and interoperable data sets for use in patient care, registries, research, and biorepositories.
Read MorePosted by Judy O'Rourke | Oct 8, 2013 | Cancer, Mass Spectrometry Reagents & Test Kits, Miscellaneous |
Improving the transfusion service’s ability to provide antigen-matched RBC units for alloimmunized patients.
Read More